Oppenheimer initiated coverage on Opiant Pharmaceuticals with a new price target

12/9/21 4:54:31 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPNT

Date	Price Target	Rating	Analyst
12/9/2021	$42.00	Outperform	Oppenheimer